Measuring Heart Muscle Stiffness in Amyloidosis Using Magnetic Resonance Imaging
Checks heart muscle stiffness with a special MRI scan in people with amyloidosis.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 14 Oct 2025
- Expected to end
- Nov 2027
- Type of study
- Observational
- Treatments tested
- Magnetic Resonance Elastography (MRE)
- Record updated
- 26 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 and older with heart (cardiac) amyloidosis of the ATTR or AL type. It tests a special MRI scan that measures how stiff the heart muscle is.
- Age
- 20 years and older
- Sex
- All sexes can join.
- Disease stage
- Cardiac amyloidosis, either ATTR or AL type, diagnosed within the last 10 years, with heart involvement shown by tests or medical records. Clinically stable, with no heart-related hospital stay in the 2 weeks before joining.
- Biomarker or test result
- ATTR type: transthyretin amyloid deposits in tissue, or a bone scan (technetium) with grade 2 or 3 heart uptake. AL type: amyloid with AL protein confirmed on tissue examination.
Main reasons for not taking part
- Cannot lie flat for 30 minutes, hold breath for 10 seconds, or walk for 6 minutes
- Cannot have an MRI safely (for example severe claustrophobia, cochlear implant, nerve stimulator)
- Has a heart pacemaker or defibrillator
- Pregnant or breast-feeding
- Weighs 155 kg (342 lb) or more
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Subjects are eligible to be included in the study if all the following criteria apply:
- Adult, age 20 and greater
- Subject is clinically stable without cardiovascular-related hospitalizations within 2 weeks prior to enrollment as assessed by the investigators
- Subject is able to provide written informed consent and is willing and able to complete study procedures
- Subject must meet criteria for either ATTR cardiac amyloidosis or AL cardiac amyloidosis from review of medical records as specified below:; ATTR cardiac amyloidosis based on meeting all the following criteria:; Diagnosis of amyloidosis within ten years prior to study screening; Transthyretin amyloid deposits in cardiac tissue OR Technetium (99mTc) bone scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness > 12 mm OR Transthyretin amyloid deposits in non-cardiac tissue with cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider; AL cardiac amyloidosis based on meeting all the following criteria:; Diagnosis of amyloidosis within ten years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness > 12 mm in the absence of other causes OR Elevated NT-proBNP (>332 ng/L) in the absence of renal failure or atrial fibrillation OR Cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider
Who cannot take part
- Unable to consent or unable to complete all study procedures 2. Unable to ambulate for 6 minutes (confirmed at study coordinator visit) 3. Unable to maintain in supine position for 30 minutes 4. Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator visit) 5. Contraindications for safe MRI scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator) 6. Presence of implantable cardiac pacemaker or defibrillator 7. History of complex congenital heart disease, prosthetic valves, prosthesis in the main pulmonary artery or ascending thoracic aorta 8. Significant artifact from prior MRI studies 9. Pregnant or breast-feeding women 10. Weight equal to or greater than 155 kg 11. In the judgment of the investigator, has clinically relevant ongoing medical condition or laboratory abnormalities or other condition that might jeopardize the participants safety, increase the participants risk from participation, interfere with the study, or confirmed study results
- Patients are ineligible to be included in the study if any of the following criteria apply:
Where in United States
- Mayo ClinicRochester, United StatesContact: Kathy BrownTaking people
About the trial
What the trial wants to find out
This is a prospective case control study to determine the feasibility and utility of myocardial stiffness assessment by cardiac magnetic resonance elastography (MRE) in patients with cardiac amyloidosis.
The group in the trial
- Cardiac Amyloidosis
Treatment: Magnetic Resonance Elastography (MRE)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Myocardial Stiffness in Amyloidosis by Magnetic Resonance Elastography - AMREloid Study
- Plain-language title
- Measuring Heart Muscle Stiffness in Amyloidosis Using Magnetic Resonance ImagingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 December 2025